Every 10-Q that Oragenics Inc. (OGEN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OGEN filings page.
Oragenics, Inc. is a development-stage biopharmaceutical company focused on intranasal ONP-002 for concussion. A Phase IIa trial in Australia has enrolled 9 participants with 34 doses administered and no serious adverse events; a Type B FDA meeting request has been submitted, with an IND targeted by end of 2026.
For the six months ended June 30, 2026, the company generated no revenue, incurred a net loss of $4.7 million, and used $4.4 million in operating cash. R&D rose to $1.8 million, and G&A was $3.0 million. Cash and cash equivalents were $3.9 million within $5.5 million of total assets and no short-term debt.
The accumulated deficit reached $231.4 million, and the auditor’s prior report and management disclosures state substantial doubt about the company’s ability to continue as a going concern, with liquidity expected to fund operations only through December 31, 2026. Capital needs are significant, and the capital structure is highly dilutive, including Series F and Series H preferred stock with anti-dilution features and warrants that could convert into tens of millions of common shares. During the quarter, John Spencer was appointed Chief Financial Officer with a base salary of $200,000.
Oragenics, Inc. reported a Q1 2026 net loss of $2.2 million, roughly flat versus Q1 2025, as it continues developing its lead concussion drug ONP-002. Operating expenses rose to $2.3 million, driven by higher research and development spending of $0.6 million as the Phase IIa trial in Australia began enrolling patients.
Cash and cash equivalents were $6.1 million at March 31, 2026, after liquidating a $4.0 million short-term investment, which management believes funds operations through year-end 2026. The company’s auditor and management highlight substantial doubt about its ability to continue as a going concern without additional financing.
The filing details significant potential dilution from Series F and Series H preferred stock and associated warrants, including an anti-dilution reset that reduced the Series H conversion price to $1.00 per share. Oragenics also signed a non-binding letter of intent to license Sigyn Therapeutics’ CardioDialysis technology for traumatic brain injury and other neurodegenerative diseases, which could involve issuing 3,250,000 new preferred shares if a definitive agreement is reached.
Oragenics (OGEN) filed its Q3 2025 10‑Q, reporting a net loss of $3.07 million for the quarter and $7.56 million year‑to‑date. Operating expenses were driven by higher G&A tied to legal and financing activity, including a $700,000 accrual for a legal settlement, while R&D rose modestly as the company prepared ONP‑002 for clinical work.
Liquidity improved significantly: cash and equivalents were $11.4 million as of September 30, 2025, reflecting a July financing of $15.2 million in net proceeds from 660,000 Series H preferred shares and accompanying warrants, and repayment of a $3.0 million short‑term note. Stockholders’ equity stood at $9.83 million. The company effected a 1‑for‑30 reverse split in June and regained NYSE American equity compliance in October.
Management continues to note substantial doubt about the company’s ability to continue as a going concern, though current cash is expected to fund operations for at least the next twelve months and support the planned ONP‑002 Phase 2a start.
Oragenics, Inc. reported a consolidated net loss of $4.49 million for the six months ended June 30, 2025, and an accumulated deficit of $221.3 million. Cash and cash equivalents were $1.97 million at June 30, 2025. The company effected a 1-for-30 reverse stock split on June 3, 2025, and its independent auditor included an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Operating expense trends show lower spend year-over-year: research and development fell ~49.6% to $791,221 for the six months and general and administrative declined ~7.7% to $2.95 million, resulting in total operating expenses of $3.74 million (down ~21.5%). Financing activity included net proceeds of $2.6 million from ATM sales in February 2025, a $3.0 million promissory note issued March 13, 2025 (subsequently repaid), and a July 2, 2025 public offering of Series H Convertible Preferred Stock and warrants that produced net proceeds of approximately $15.2 million, which the company states extends its cash runway into the first half of 2026. The filing discloses a pending dispute with Ladenburg Thalmann and anti-dilution provisions in the Series H terms.